• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Coats Lonnel bought $94,797 worth of shares (90,000 units at $1.05), increasing direct ownership by 11% to 914,359 units (SEC Form 4)

    11/17/23 4:55:09 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LXRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    COATS LONNEL

    (Last) (First) (Middle)
    2445 TECHNOLOGY FOREST BLVD.
    11TH FLOOR

    (Street)
    THE WOODLANDS TX 77381

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    LEXICON PHARMACEUTICALS, INC. [ LXRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    11/16/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/16/2023 P 90,000 A $1.0533(1) 914,359 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This transaction was executed in multiple trades at prices ranging from $1.05 to $1.06 per share. The price reported above reflects the weighted average purchase price of such trades. Mr. Coats hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which this transaction was effected.
    /s/ Lonnel Coats 11/17/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LXRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LXRX

    DatePrice TargetRatingAnalyst
    3/5/2025$2.00 → $1.00Outperform → Market Perform
    Leerink Partners
    6/17/2024$10.00Buy
    H.C. Wainwright
    4/30/2024$5.00Outperform
    Leerink Partners
    3/7/2023$3.00Hold
    Jefferies
    8/12/2022$10.00Overweight
    Piper Sandler
    More analyst ratings

    $LXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

    – Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 pilavapadin program at the 19th Annual Pain Therapeutics Summit. These data follow the topline results from the Phase 2b PROGRESS study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) announced in March of 2025, which identified 10 mg once daily as the most clinically meaningful and appropriate dose to advance into

    10/14/25 8:00:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

    THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) hosted and participated in a roundtable discussion with experts to explore how to enhance current and future legislative and policy efforts to better meet the needs of Americans suffering from chronic pain. The perspectives of clinicians, patient advocacy groups, and individuals were shared during the half-day meeting conducted at the Biotechnology Innovation Organization (BIO) headquarters in Washington, DC. According to the U.S. Pain Foundation, approximately 50 million Americans suffer from chronic pain and pain conditions cost as much as $635 million yearly in direct health c

    10/8/25 7:59:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

    Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting now expected during the fourth quarter THE WOODLANDS, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced an update to the previous submission of additional clinical data to the U.S. Food and Drug Administration (FDA) from ongoing third-party funded, investigator-initiated studies supporting the potential resubmission of the New Drug Application for Zynquista®

    9/22/25 4:00:00 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Coats Lonnel bought $94,797 worth of shares (90,000 units at $1.05), increasing direct ownership by 11% to 914,359 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    11/17/23 4:55:09 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coats Lonnel bought $10,100 worth of shares (10,000 units at $1.01), increasing direct ownership by 1% to 824,359 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    11/13/23 5:31:49 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Debbane Raymond bought $1,103,957 worth of shares (1,000,000 units at $1.10), increasing direct ownership by 293% to 1,340,847 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    10/12/23 4:01:18 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lexicon Pharma downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Lexicon Pharma from Outperform to Market Perform and set a new price target of $1.00 from $2.00 previously

    3/5/25 7:37:06 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Lexicon Pharma with a new price target

    H.C. Wainwright initiated coverage of Lexicon Pharma with a rating of Buy and set a new price target of $10.00

    6/17/24 7:36:12 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Lexicon Pharma with a new price target

    Leerink Partners initiated coverage of Lexicon Pharma with a rating of Outperform and set a new price target of $5.00

    4/30/24 6:26:57 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    SEC Filings

    View All

    SEC Form S-8 filed by Lexicon Pharmaceuticals Inc.

    S-8 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

    8/6/25 4:41:56 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lexicon Pharmaceuticals Inc.

    10-Q - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

    8/6/25 4:15:08 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

    8/6/25 7:31:54 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Gopinathan Suma claimed ownership of 74,520 shares (SEC Form 3)

    3 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    6/9/25 10:03:46 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Martens Rachel Yap claimed no ownership of stock in the company (SEC Form 3)

    3 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    6/6/25 5:40:27 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Swain Judith L

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    6/3/25 4:25:29 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Leadership Updates

    Live Leadership Updates

    View All

    Lexicon Appoints Scott Coiante as Chief Financial Officer

    THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Agile Therapeutics Inc. from August 2023 to August 2024, as well as from 2011-2019. "I am pleased to join Lexicon at this pivotal moment for the company and eager to contribute to its

    1/2/25 8:00:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Appoints Ivan H. Cheung to Board of Directors

    THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manager TPG – since September 2023. "I am honored to join the Lexicon Board of Directors at this pivotal moment in the company's history, and to support its mis

    11/20/24 4:05:47 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

    THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis. "I am confident that Mike is the right person to serve as Lexicon's next chief executive officer at this critical time for the company," said Ray Debbane, chairman of Lexicon's board of directors. "He is an inspiring leader with a demonstrated track record of success, includi

    7/8/24 9:15:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

    SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    11/14/24 4:26:14 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

    SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    11/12/24 10:32:10 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LXRX
    Financials

    Live finance-specific insights

    View All

    Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended June 30, 2025, and provided an update on key corporate milestones and accomplishments.  "We continue t

    8/6/25 7:30:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

    THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast

    7/23/25 8:00:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

    Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2025, and provided an update on key corporate milestones and accomplishments. "We began 2025 delivering on three of our goals for

    5/13/25 4:00:00 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care